FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220863005> ?p ?o ?g. }

• W4220863005 endingPage "652" @default.
• W4220863005 startingPage "642" @default.
• W4220863005 abstract "Aims Immune checkpoint inhibitors (ICIs) are used in incurable urothelial cancers, both in chemo-naïve and platinum-refractory patients. Efficacy and toxicity data published outside controlled clinical trials are limited. We report overall survival, progression-free survival and toxicities of ICIs in locally advanced (LABC) or metastatic bladder cancer (MBC). We aimed to develop and validate a prognostic model for these patients. Materials and methods A multicentre real-world individual patient-level data study (n = 272) evaluating ICIs in the first-line platinum-ineligible or platinum-refractory setting for LABC/MBC between March 2017 and February 2020 was undertaken. Cox regression analyses evaluated the association of prognostic factors with overall survival. Data were split to create a training (n = 208) and validation (n = 64) cohort. The backward elimination method with a P-value cut-off of 0.05 was used to develop a reduced prognostic model using the training data set. The concordance index and assessment of observed versus predicted survival probabilities were used to evaluate the final model. Results The median follow-up was 18.9 (15.8–21.5) months. The median overall survival and progression-free survival in the training cohort were 9.2 (95% confidence interval 7.4–10.5) and 4.5 months (3.5–5.7), respectively. The most common grade 1/2 adverse events recorded were fatigue (47.8%) and infection (19.9%). Five key prognostic factors found in the training set were low haemoglobin, high neutrophil count, choice of immunotherapy favouring pembrolizumab, presence of liver metastasis and steroid use within 30 days of treatment. The concordance index for the training and validation cohorts was 0.66 (standard error = 0.05) and 0.64 (standard error = 0.04), respectively, for the final model. A nomogram was developed to calculate the expected survival probabilities based on risk factors. Conclusions Real-world data were used to produce a validated prognostic model for overall survival in LABC/MBC treated with ICIs. This model could assist in patient stratification, interpreting and framing future trials incorporating PD-1/PD-L1 inhibitors in LABC/MBC." @default.
• W4220863005 created "2022-04-03" @default.
• W4220863005 creator A5005989132 @default.
• W4220863005 creator A5018906200 @default.
• W4220863005 creator A5019119302 @default.
• W4220863005 creator A5020453607 @default.
• W4220863005 creator A5029693414 @default.
• W4220863005 creator A5032380594 @default.
• W4220863005 creator A5033956695 @default.
• W4220863005 creator A5034096708 @default.
• W4220863005 creator A5038302500 @default.
• W4220863005 creator A5041859071 @default.
• W4220863005 creator A5043628967 @default.
• W4220863005 creator A5046914918 @default.
• W4220863005 creator A5048550515 @default.
• W4220863005 creator A5048720408 @default.
• W4220863005 creator A5054724709 @default.
• W4220863005 creator A5073735985 @default.
• W4220863005 date "2022-10-01" @default.
• W4220863005 modified "2023-10-01" @default.
• W4220863005 title "Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy" @default.
• W4220863005 cites W2066948081 @default.
• W4220863005 cites W2105737543 @default.
• W4220863005 cites W2109930846 @default.
• W4220863005 cites W2132379894 @default.
• W4220863005 cites W2140478525 @default.
• W4220863005 cites W2261598422 @default.
• W4220863005 cites W2270932386 @default.
• W4220863005 cites W2414977199 @default.
• W4220863005 cites W2560432428 @default.
• W4220863005 cites W2582671354 @default.
• W4220863005 cites W2588916311 @default.
• W4220863005 cites W2607272476 @default.
• W4220863005 cites W2771737095 @default.
• W4220863005 cites W2777192533 @default.
• W4220863005 cites W2792066576 @default.
• W4220863005 cites W2802496191 @default.
• W4220863005 cites W2883706035 @default.
• W4220863005 cites W2890298405 @default.
• W4220863005 cites W2894582328 @default.
• W4220863005 cites W2927051995 @default.
• W4220863005 cites W2938353934 @default.
• W4220863005 cites W2943108118 @default.
• W4220863005 cites W2964014383 @default.
• W4220863005 cites W2988124258 @default.
• W4220863005 cites W2994329501 @default.
• W4220863005 cites W2994692693 @default.
• W4220863005 cites W3004373987 @default.
• W4220863005 cites W3087464965 @default.
• W4220863005 cites W3087466624 @default.
• W4220863005 cites W3107738233 @default.
• W4220863005 cites W3115265739 @default.
• W4220863005 cites W3118924526 @default.
• W4220863005 cites W3127912627 @default.
• W4220863005 cites W3152739953 @default.
• W4220863005 cites W3163490080 @default.
• W4220863005 cites W2955717253 @default.
• W4220863005 doi "https://doi.org/10.1016/j.clon.2022.02.022" @default.
• W4220863005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35282933" @default.
• W4220863005 hasPublicationYear "2022" @default.
• W4220863005 type Work @default.
• W4220863005 citedByCount "5" @default.
• W4220863005 countsByYear W42208630052022 @default.
• W4220863005 countsByYear W42208630052023 @default.
• W4220863005 crossrefType "journal-article" @default.
• W4220863005 hasAuthorship W4220863005A5005989132 @default.
• W4220863005 hasAuthorship W4220863005A5018906200 @default.
• W4220863005 hasAuthorship W4220863005A5019119302 @default.
• W4220863005 hasAuthorship W4220863005A5020453607 @default.
• W4220863005 hasAuthorship W4220863005A5029693414 @default.
• W4220863005 hasAuthorship W4220863005A5032380594 @default.
• W4220863005 hasAuthorship W4220863005A5033956695 @default.
• W4220863005 hasAuthorship W4220863005A5034096708 @default.
• W4220863005 hasAuthorship W4220863005A5038302500 @default.
• W4220863005 hasAuthorship W4220863005A5041859071 @default.
• W4220863005 hasAuthorship W4220863005A5043628967 @default.
• W4220863005 hasAuthorship W4220863005A5046914918 @default.
• W4220863005 hasAuthorship W4220863005A5048550515 @default.
• W4220863005 hasAuthorship W4220863005A5048720408 @default.
• W4220863005 hasAuthorship W4220863005A5054724709 @default.
• W4220863005 hasAuthorship W4220863005A5073735985 @default.
• W4220863005 hasBestOaLocation W42208630052 @default.
• W4220863005 hasConcept C121608353 @default.
• W4220863005 hasConcept C126322002 @default.
• W4220863005 hasConcept C143998085 @default.
• W4220863005 hasConcept C160798450 @default.
• W4220863005 hasConcept C2776694085 @default.
• W4220863005 hasConcept C2777701055 @default.
• W4220863005 hasConcept C2780057760 @default.
• W4220863005 hasConcept C2780352672 @default.
• W4220863005 hasConcept C2780739268 @default.
• W4220863005 hasConcept C34626388 @default.
• W4220863005 hasConcept C44249647 @default.
• W4220863005 hasConcept C50382708 @default.
• W4220863005 hasConcept C71924100 @default.
• W4220863005 hasConcept C72563966 @default.
• W4220863005 hasConceptScore W4220863005C121608353 @default.
• W4220863005 hasConceptScore W4220863005C126322002 @default.

• next